FDA Approval Alert: The Need-to-Know | Inavolisib/Palbociclib/Fulvestrant in PIK3CA+ Advanced Breast Cancer

In October 2024, the FDA approved inavolisib in combination with palbociclib and fulvestrant for those with endocrine-resistant, hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer harboring PIK3CA mutations.

Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer
Article
Oct 10, 2024 8:10 PM
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.